Biopsy Procedure (NCT05408845)

Name: Biopsy Procedure trial for Metastatic Salivary Gland Carcinoma (NCT05408845)
Uploaded: 2026-10-31T21:57:27.403Z
Duration: 1 min 30 s
Description: Biopsy Procedure trial for Metastatic Salivary Gland Carcinoma (NCT05408845). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05408845.

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers: a one-minute explainerNCT054088451 min

Biopsy Procedure trial for Metastatic Salivary Gland Carcinoma (NCT05408845). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with recurrent, metastatic or unresectable salivary-gland cancer expressing HER2. Prior-treatment limits differ between HER2-positive and HER2-low groups.

The idea: target HER2 to block growth or deliver chemotherapy. HER2-positive patients are randomized to docetaxel plus trastuzumab or trastuzumab emtansine. HER2-low patients receive trastuzumab deruxtecan in a separate group. Treatments are intravenous, every three weeks; docetaxel is limited to six cycles.

This phase 2 study plans 146 patients. Alan Ho leads the NRG Oncology study, with 143 recruiting US sites. Researchers measure disease control and response.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.